Literature DB >> 21160959

Recent insights on risk factors of hepatocellular carcinoma.

Nabil Mohie Abdel-Hamid1.   

Abstract

Hepatocellular carcinoma (HCC) is a disease prevalent in many populations worldwide. It initiates many economic and health problems in management modalities and leads to increasing mortality rates. Worldwide, trials have attempted to discover specific early markers for detection and prediction of the disease, hoping to set a more precise strategy for liver cancer prevention. Unfortunately, many economic, cultural and disciplinary levels contribute to confounding preventive strategies. Many risk factors contribute to predisposition to HCC, which can present individually or simultaneously. Previous articles discussed many risk factors for hepatocellular carcinogenesis; however, most of them didn't consider collectively the most recent data relating to causes. In this article, the pathogenesis and risk factors of HCC are discussed. Most of the intermediary steps of HCC involve molecular and transcriptional events leading to hepatocyte malignant transformation. These steps are mainly triggered by hepatitis B, C or transfusion-transmitted virus, either alone, or with other factors. Diabetes seems to be a major contributing risk factor. Schistosomiasis, a blood infestation, mostly affects Nile basin inhabitants leading to bladder, renal and hepatic cancers. Alcoholism, food and water pollutants and some drugs can also lead to HCC. Additionally, some hereditary diseases, as hemochromatosis, α-1-antitrypsin deficiency and tyrosinaemia are known to lead to the development of HCC, if not well managed.

Entities:  

Keywords:  Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Risk, Alcoholism and hereditary diseases; Schistosomiasis; Transfusion-transmitted virus

Year:  2009        PMID: 21160959      PMCID: PMC2999255          DOI: 10.4254/wjh.v1.i1.3

Source DB:  PubMed          Journal:  World J Hepatol


  39 in total

1.  In situ polymerase chain reaction detection of transfusion-transmitted virus in liver biopsy.

Authors:  M Comar; F Ansaldi; L Morandi; G Dal Molin; P M Foschini; S L Crocè; S Bonin; G Stanta; C Tiribelli; C Campello
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

2.  Hepatitis C virus infection and hepatosplenic schistosomiasis.

Authors:  S Bassily; K C Hyams; N A el-Masry; N F Hassan; D M Watts
Journal:  Scand J Infect Dis       Date:  1992

3.  Transfusion-transmitted virus prevalence in Turkish patients with thalassemia.

Authors:  Emel Ozyürek; Koray Ergünay; Baris Kuskonmaz; Selma Unal; Mualla Cetin; Semsettin Ustaçelebi; Aytemiz Gürgey; Fatma Gümrük
Journal:  Pediatr Hematol Oncol       Date:  2006-06       Impact factor: 1.969

4.  Endogenous bile acids as carcinogens.

Authors:  Peter L M Jansen
Journal:  J Hepatol       Date:  2007-06-14       Impact factor: 25.083

5.  Excess risk of primary liver cancer in patients with diabetes mellitus.

Authors:  H O Adami; W H Chow; O Nyrén; C Berne; M S Linet; A Ekbom; A Wolk; J K McLaughlin; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

6.  Histopathological and morphometric analysis of atypical adenomatous hyperplasia of human cirrhotic livers.

Authors:  T Terada; K Ueda; Y Nakanuma
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  R Yamaguchi; H Yano; A Iemura; S Ogasawara; M Haramaki; M Kojiro
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

Review 8.  Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.

Authors:  M A Moore; C B Park; H Tsuda
Journal:  Eur J Cancer Prev       Date:  1998-04       Impact factor: 2.497

9.  Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells.

Authors:  D Sakamuro; T Furukawa; T Takegami
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase.

Authors:  M Gale; B Kwieciszewski; M Dossett; H Nakao; M G Katze
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

View more
  5 in total

1.  The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; M H Nazmy; A Farhan; K Thabet
Journal:  Environ Health Prev Med       Date:  2015-03-01       Impact factor: 3.674

2.  Hepatocellular carcinoma in Asia: Prevention strategy and planning.

Authors:  Sara Ashtari; Mohamad Amin Pourhoseingholi; Afsaneh Sharifian; Mohamad Reza Zali
Journal:  World J Hepatol       Date:  2015-06-28

3.  New insights on non-B non-C hepatocellular carcinoma in mid Delta Region, Egypt.

Authors:  Abdel Raouf Abou El Azm; Mohamed Yousef; Nagwa Mansour; Aymen Awad; Samia El Dardiry; Ibrahim Abdel Aziz
Journal:  J Gastrointest Cancer       Date:  2014-09

Review 4.  Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction.

Authors:  Yusuke Kanda; Mitsuhiko Osaki; Futoshi Okada
Journal:  Int J Mol Sci       Date:  2017-04-19       Impact factor: 5.923

5.  Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma.

Authors:  Abdel Raouf Abou El Azm; Mohamed Yousef; Raafat Salah; Wael Mayah; Salwa Tawfeek; Hussien Ghorabah; Nagwa Mansour
Journal:  Springerplus       Date:  2013-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.